- Home
- BCYC vs DCTH Comparison
BCYC vs DCTH Comparison
Compare BCYC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- DCTH
- Stock Information
- Founded
- BCYC 2009
- DCTH 1988
- Country
- BCYC United Kingdom
- DCTH United States
- Employees
- BCYC N/A
- DCTH N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- BCYC Health Care
- DCTH Health Care
- Exchange
- BCYC Nasdaq
- DCTH Nasdaq
- Market Cap
- BCYC 566.5M
- DCTH 630.4M
- IPO Year
- BCYC 2019
- DCTH N/A
- Fundamental
- Price
- BCYC $7.42
- DCTH $13.85
- Analyst Decision
- BCYC Buy
- DCTH Strong Buy
- Analyst Count
- BCYC 10
- DCTH 4
- Target Price
- BCYC $25.00
- DCTH $24.00
- AVG Volume (30 Days)
- BCYC 223.0K
- DCTH 508.4K
- Earning Date
- BCYC 08-05-2025
- DCTH 08-04-2025
- Dividend Yield
- BCYC N/A
- DCTH N/A
- EPS Growth
- BCYC N/A
- DCTH N/A
- EPS
- BCYC N/A
- DCTH N/A
- Revenue
- BCYC $25,722,000.00
- DCTH $53,850,000.00
- Revenue This Year
- BCYC $7.35
- DCTH $155.42
- Revenue Next Year
- BCYC N/A
- DCTH $37.93
- P/E Ratio
- BCYC N/A
- DCTH N/A
- Revenue Growth
- BCYC N/A
- DCTH 1068.87
- 52 Week Low
- BCYC $6.10
- DCTH $7.17
- 52 Week High
- BCYC $28.67
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- BCYC 36.14
- DCTH 37.03
- Support Level
- BCYC $8.33
- DCTH $15.72
- Resistance Level
- BCYC $8.63
- DCTH $17.35
- Average True Range (ATR)
- BCYC 0.50
- DCTH 0.74
- MACD
- BCYC -0.13
- DCTH -0.40
- Stochastic Oscillator
- BCYC 7.18
- DCTH 2.23
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.